Guruduth Banavar

So in the last...

Three randomized placebo-controlled trials that we have done, we have an arm that is looking at just placebo supplements.

Like, you know, you get the same shape supplements, and they just have inert substance in them.

And the other group has an intervention which is coming from our algorithms, the AI algorithms.

And we see that there's a significant difference in the improvement of the intervention arm compared to the control arm.

When it's placebo controlled.

So that's the kind of the, call it the gold standard science with which we prove that our recommendations and our science at the end of the day works in a positive way for people.

This is exactly the key for us, right?

The earlier that you detect the better, right?

Chronic disease, let's just talk about chronic disease for a minute, right?

So when we talk about metabolic diseases like diabetes and non-alcoholic fatty liver disease and other things, right?

These develop many years, maybe decades before it actually shows up.

Cardiovascular disease, right?

Before a person has a heart attack,

There is probably like five years before there are markers in your blood, in your microbiome, in your oral cavity and so forth.

So what we do in Viome is to try to detect those very, very early markers so we can give you the advance warning.

We give you early warning and say, hey, look, your pathway for TMA production is not doing great.

in your gut, right?

TMA production can get converted into TMAO when it translocates into your bloodstream, and that can create plaque, it can create atherosclerosis, it can create cardiovascular disease, heart attack at the end, right?

So we can detect when your TMA pathways are not optimal or suboptimal,